Compare AAPG & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAPG | VCYT |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | N/A | 2013 |
| Metric | AAPG | VCYT |
|---|---|---|
| Price | $23.88 | $32.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $48.50 | $45.13 |
| AVG Volume (30 Days) | 1.7K | ★ 806.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 164.52 |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.33 |
| Revenue Next Year | $368.64 | $12.53 |
| P/E Ratio | ★ N/A | $39.88 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.56 | $22.61 |
| 52 Week High | $48.45 | $50.71 |
| Indicator | AAPG | VCYT |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 34.02 |
| Support Level | $23.06 | $32.51 |
| Resistance Level | $26.01 | $32.79 |
| Average True Range (ATR) | 0.93 | 1.44 |
| MACD | 0.13 | -0.20 |
| Stochastic Oscillator | 62.79 | 3.92 |
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.